Skip to content
Screener

Kura Oncology KURA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$487K+29.2%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$428K+34.2%
Nuvation Bio logo
Nuvation BioNUVB
$1.72M-5.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$409K-25.1%
Incyte logo
IncyteINCY
$5.59M-9.5%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$849.57M+76.7%
Enterprise value$834.76M+99.5%
P/S11.9×+3.3×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219481
Line itemMarch 31, 2026December 31,2025
Current liabilities
Accounts payable$7,043$5,017
Accrued expenses and other current liabilities45,46661,697
Current operating lease liabilities1,2831,277
Current portion of contract liabilities47,70448,983
Total current liabilities101,496116,974
Long-term debt, net9,7499,711
Long-term operating lease liabilities13,2419,469

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Kura Oncology's operating lease liabilities (current)?
Kura Oncology (KURA) reported operating lease liabilities (current) of $1.28M in Q1 2026.
How has Kura Oncology's operating lease liabilities (current) changed year-over-year?
Kura Oncology's operating lease liabilities (current) decreased by 32.7% year-over-year, from $1.91M to $1.28M.
What is the long-term trend for Kura Oncology's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Kura Oncology's operating lease liabilities (current) has grown at a -9.4% compound annual growth rate (CAGR), from $2.09M to $1.28M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Kura Oncology's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude